시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 경피 약물전달 기기 시장: 시장 인사이트, 경쟁 구도 및 시장 예측(-2032년)
Transdermal Drug Delivery Devices - Market Insights, Competitive Landscape, and Market Forecast - 2032
상품코드 : 1656902
리서치사 : DelveInsight
발행일 : On Demand Report
페이지 정보 : 영문 150 Pages
 라이선스 & 가격 (부가세 별도)
US $ 3,750 ￦ 5,427,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 4,688 ￦ 6,785,000
PDF (2-3 User License) help
PDF 보고서를 동일 사업장에서 3명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 5,625 ￦ 8,141,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 7,500 ￦ 10,855,000
PDF (Global License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

경피 약물전달 기기 시장 규모는 2024년 715억 6,627만 달러에서 예측 기간 동안 연평균 6.91%의 연평균 복합 성장률(CAGR)로 성장하여 2032년에는 1,217억 9,876만 달러 규모로 성장할 것으로 예측됩니다.

만성질환의 유병률 증가와 3세대 경피적 약물 전달 장치의 채택이 확대됨에 따라 이러한 장치 세계 시장이 크게 성장하고 있습니다. 기술 발전으로 인해 장치의 효율성이 향상되어 약물 흡수와 환자 편의성이 개선되고 있습니다. 또한 호르몬 질환, 심혈관 질환, 통증 관리 등 다양한 분야에 적용할 수 있고, 비침습적이고, 제어가 용이하며, 환자 친화적인 약물 전달 옵션을 제공한다는 점이 수요를 더욱 촉진하고 있습니다. 이러한 요인들이 복합적으로 작용하여 2025년부터 2032년까지 예측 기간 동안 경피적 약물 전달 장치의 사용 및 개발이 전 세계적으로 확대될 것으로 예상됩니다.

유형별로는 약물 함유 접착 패치 부문이 2024년 55.44%의 점유율을 차지하며 시장을 장악할 것으로 예상됩니다. 이러한 접착 패치가 제공하는 다양한 장점과 용도가 예측 기간 동안 수요를 견인할 것으로 예상됩니다. 약물 함유 접착식 경피 패치는 피부에서 혈류로 약물을 전달하도록 설계된 약물 전달 시스템의 일종입니다. 이 패치는 시간이 지남에 따라 약물을 방출하도록 설계되어 제어되고 일관된 치료 용량을 제공하도록 설계되었습니다. 접착층은 패치를 피부에 부착하고 약물 방출 속도를 조절하는 데 도움을 줍니다. 패치가 피부에 부착되면 약물이 점차적으로 피부에서 혈류로 확산되어 시간이 지남에 따라 안정적이고 통제된 약물 방출이 이루어집니다.

지역별로는 북미가 2024년 45.39%로 가장 큰 점유율을 차지할 것으로 예상되며, 예측 기간 동안 5.91%의 연평균 복합 성장률(CAGR)로 성장할 것으로 예상됩니다. 이는 이 지역의 만성 통증, 중추신경계 질환, 심혈관 질환과 같은 대상 질환의 유병률 증가, 신제품 출시, 연구개발 활동에 대한 집중도가 높아졌기 때문으로 분석됩니다.

세계의 경피 약물전달 기기(Transdermal Drug Delivery Device) 시장을 조사했으며, 시장 개요, 시장 영향요인 및 시장 기회 분석, 법 및 규제 환경, 시장 규모 추이와 예측, 각종 부문별/지역별/주요 국가별 상세 분석, 경쟁 구도, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.

목차

제1장 경피 약물전달 기기 시장 보고서 : 서론

제2장 경피 약물전달 기기 시장 : 주요 요약

제3장 경쟁 구도

제4장 규제 분석

제5장 경피 약물전달 기기 시장 : 주요 요인 분석

제6장 경피 약물전달 기기 시장 : Porter의 Five Forces 분석

제7장 경피 약물전달 기기 시장 평가

제8장 경피 약물전달 기기 시장 : 기업 및 제품 개요

제9장 KOL(Key Opinion Leader)의 견해

제10장 프로젝트 접근

제11장 DelveInsight에 대해

제12장 면책사항 및 문의

LSH
영문 목차

영문목차

Transdermal Drug Delivery Devices Market by Type (Drug-in-adhesive Patches, Matrix Patches, Reservoir Membrane Patches, and Microneedle Patches), Application (Pain Management, Central Nervous System Disorders, Hormonal Applications, Cardiovascular Disorders, and Others), End-User (Hospitals, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the increasing prevalence of chronic conditions, increase in adoption of third-generation transdermal drug delivery devices, technological advancements observed in the device, and use of these devices from hormonal disorders to cardiovascular conditions and pain management across the globe.

The transdermal drug delivery devices market was valued at USD 71,566.27 million in 2024, growing at a CAGR of 6.91% during the forecast period from 2025 to 2032 to reach USD 121,798.76 million by 2032. The growing prevalence of chronic conditions, coupled with the increasing adoption of third-generation transdermal drug delivery devices, is significantly boosting the global market for these devices. Technological advancements have enhanced device efficiency, improving drug absorption and patient convenience. Their versatile application across hormonal disorders, cardiovascular conditions, and pain management further drives demand, offering a non-invasive, controlled, and patient-friendly alternative for drug delivery. Together, these factors contribute to the expanding use and development of transdermal drug delivery devices worldwide during the forecast period from 2025 to 2032.

Transdermal Drug Delivery Devices Market Dynamics:

According to recent data provided by the British Heart Foundation (2024), globally, approximately 620 million people, or about 1 in 13 individuals, live with heart and circulatory diseases.

Furthermore, as per the recent data provided by the British Heart Foundation (2024), coronary (ischemic) heart disease, the most commonly diagnosed worldwide, affects an estimated 200 million people globally. Approximately 110 million men and 80 million women are affected. Additionally, around 56 million women and 45 million men are stroke survivors. It is estimated that at least 13 million people worldwide live with congenital heart disease, with potentially millions more undiagnosed. As the prevalence of CVDs rises globally, particularly among aging populations and individuals with sedentary lifestyles, the need for convenient, long-term treatment solutions has intensified. Thus, transdermal drug delivery devices allow for controlled and consistent delivery of medications like antihypertensives, antianginal drugs, and anticoagulants, ensuring better therapeutic outcomes and improved patient compliance thereby boosting the overall market across the globe.

Additionally, as per the recent data provided by the World Health Organization (2024), epilepsy affects approximately 50 million people worldwide, making it one of the most prevalent neurological disorders globally. Thus, with the rising prevalence of neurological disorders, there is a growing demand for non-invasive and effective treatment methods. These transdermal drug delivery devices provide controlled and consistent delivery of medications, bypassing the gastrointestinal tract and reducing side effects often associated with oral or injectable therapies thereby boosting the market of transdermal drug delivery devices across the globe.

Additionally, the increase in strategic activities among the key market players is further boosting the market of transdermal drug delivery devices across the globe. For instance, in January 2024, Starton Therapeutics announced the launch of STARSILON a novel proprietary transdermal patch delivery platform.

Thus, the factors mentioned above are expected to boost the overall market of transdermal drug delivery devices across the globe during the forecast period from 2025 to 2032.

However, disadvantages associated with transdermal drug delivery devices such as irritation at the site of application edema and increased product recalls may hinder the future market of transdermal drug delivery devices across the globe during the forecasted period.

Transdermal Drug Delivery Devices Market Segment Analysis:

Transdermal Drug Delivery Devices Market by Type (Drug-in-adhesive Patches, Matrix Patches, Reservoir Membrane Patches, and Microneedle Patches), Application (Pain Management, Central Nervous System Disorders, Hormonal Applications, Cardiovascular Disorders, and Others), End-User (Hospitals, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

The drug-in-adhesive patches category in the transdermal drug delivery devices market is estimated to dominate the market with a market share of 55.44% in 2024. This can be attributed to the various advantages and applications provided by these adhesive patches which will be responsible for driving the demand for transdermal drug delivery devices market during the given forecast period. Drug-in-adhesive transdermal patches are a type of drug delivery system designed to deliver drugs through the skin and into the bloodstream. These patches are designed to release the drug over time, providing a controlled and consistent therapeutic dosage. The adhesive layer adheres the patch to the skin and also helps to control the rate at which the drug is released. When the patch is applied to the skin, the drug gradually diffuses through the skin and into the bloodstream, providing a steady and controlled release of medication over time.

Drug-in-adhesive transdermal patches are easy to apply and do not require needles or invasive procedures, making them more convenient and patient-friendly. These drug delivery systems provide a controlled and consistent release of medication over a prolonged period, which helps to maintain stable drug levels in the bloodstream. Further presence of some key products in the market such as TRANSDERM-V by Novartis and Mylan-rivastigmine Patch 10 by Viatris Inc. will also contribute in propelling the growth of this category.

Hence, owing to the above-mentioned factors, the market for drug-in-adhesive will experience increased demand, thus driving the overall transdermal drug delivery devices market during the forecast period.

North America is expected to dominate the overall transdermal drug delivery devices market:

Among all regions, North America is estimated to hold the largest share of 45.39% in the global transdermal drug delivery devices market in 2024, growing at a CAGR of 5.91% during the forecast period from 2025 to 2032. This can be attributed to the growing prevalence of targeted diseases such as chronic pain, central nervous system disorders, and cardiovascular diseases in the region, new product launches, and the increased focus on research and development activities among other factors that are driving the overall growth of the transdermal drug delivery devices market over the forecast period.

According to recent data from the Centers for Disease Control and Prevention (2024), approximately 4.9% of adults were diagnosed with coronary heart disease in 2022. Furthermore, by 2023, an estimated 12.1 million individuals in the United States were projected to have atrial fibrillation. Additionally, each year, over 795,000 people in the U.S. experience a stroke, with around 610,000 of these being first-time strokes. Notably, nearly 185,000 of these strokes, or about one in four, occur in individuals who have previously had a stroke.

Additionally, as per the recent data provided by the Alzheimer's Association, in 2024, approximately 6.9 million Americans age 65 and older are living with Alzheimer's. Furthermore, as per the recent data provided by the Parkinson's Foundation (2022), nearly 90,000 people are diagnosed with Parkinson's disease in the U.S. each year and approximately one million people in the U.S. are living with Parkinson's disease (PD). This number is expected to rise to 1.2 million by 2030. Thus, the rising prevalence of these diseases, coupled with the demand for patient-friendly solutions that improve adherence and reduce systemic side effects, is accelerating the adoption of transdermal technologies.

Furthermore, the increasing number of product development activities in the region is further going to accelerate the growth of the spinal non-fusion devices market. For instance, in February 2024, LTS LOHMANN Therapie-Systeme AG announced the launch of the UDENYCA(R) on-body injector (OBI) through its Sorrel(TM) platform. UDENYCA(R) (pegfilgrastim-cbqv) aims to reduce infection risks post-chemotherapy. The FDA approved the device in December 2023, enhancing patient convenience and drug administration at home.

Thus, the above-mentioned factors are expected to escalate the market of transdermal drug delivery devices in the region.

Transdermal Drug Delivery Devices Market Key Players:

Some of the key market players operating in the transdermal drug delivery devices market include Novartis, Viatris Inc., UCB SA, Hisamitsu Pharmaceutical, Boehringer Ingelheim, Johnson & Johnson Services Inc., Purdue Pharma, Bayer AG, Haleon Group of Companies, Ingenus Pharmaceuticals, Luye Pharma Group, Cumberland Pharmaceuticals Inc., Sanofi, Sparsha Pharma International Pvt Ltd., Cipla, and others.

Recent Developmental Activities in the Transdermal Drug Delivery Devices Market:

Key Takeaways From the Transdermal Drug Delivery Devices Market Report Study

Target Audience Who Can be Benefited From This Transdermal Drug Delivery Devices Market Report Study

Frequently Asked Questions for the Transdermal Drug Delivery Devices Market:

1. What are transdermal drug delivery devices?

2. What is the market for transdermal drug delivery devices?

3. What are the drivers for the global transdermal drug delivery devices market?

4. Who are the key players operating in the global transdermal drug delivery devices market?

5. Which region has the highest share in the global transdermal drug delivery devices market?

Table of Contents

1. Transdermal Drug Delivery Devices Market Report Introduction

2. Transdermal Drug Delivery Devices Market Executive Summary

3. Competitive Landscape

4. Regulatory Analysis

5. Transdermal Drug Delivery Devices Market Key Factors Analysis

6. Transdermal Drug Delivery Devices Market Porter's Five Forces Analysis

7. Transdermal Drug Delivery Devices Market Assessment

8. Transdermal Drug Delivery Devices Market Company and Product Profiles

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기